KAPA
Income statement / Annual
Last year (2024), Kairos Pharma, Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Kairos Pharma, Ltd.'s net income was -$2.60 M.
See Kairos Pharma, Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$414,000.00
|
$82,000.00
|
$87,000.00
|
$183,000.00
|
$20,000.00
|
| General & Administrative Expenses |
$1.93 M
|
$1.47 M
|
$324,000.00
|
$1.66 M
|
$1.03 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.93 M
|
$1.47 M
|
$324,000.00
|
$1.66 M
|
$1.03 M
|
| Other Expenses |
$0.00
|
$160,000.00
|
$160,000.00
|
$98,000.00
|
$0.00
|
| Operating Expenses |
$2.34 M
|
$1.71 M
|
$571,000.00
|
$1.94 M
|
$1.05 M
|
| Cost And Expenses |
$0.00
|
$1.71 M
|
$571,000.00
|
$1.94 M
|
$1.05 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$35,000.00
|
$98,000.00
|
$479,000.00
|
$202,000.00
|
$5,411.00
|
| Depreciation & Amortization |
$295,000.00
|
$160,000.00
|
$160,000.00
|
$98,000.00
|
-$58.00
|
| EBITDA |
-$2.34 M |
-$1.55 M |
-$431,000.00 |
-$1.88 M |
-$1.05 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$260,000.00
|
-$98,000.00
|
-$479,000.00
|
-$202,000.00
|
-$5,469.00
|
| Income Before Tax |
-$2.60 M
|
-$1.81 M
|
-$1.05 M
|
-$2.15 M
|
-$1.05 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$2.60 M
|
-$1.81 M
|
-$1.05 M
|
-$2.15 M
|
-$1.05 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.23 |
-0.17 |
-0.1 |
-0.17 |
-0.0937 |
| EPS Diluted |
-0.23 |
-0.17 |
-0.1 |
-0.17 |
-0.0937 |
| Weighted Average Shares Out |
$11.36 M
|
$10.38 M
|
$10.24 M
|
$12.84 M
|
$11.22 M
|
| Weighted Average Shares Out Diluted |
$11.36 M
|
$10.38 M
|
$10.24 M
|
$12.84 M
|
$11.22 M
|
| Link |
|
|
|
|
|
